RxDoctor Payments Data

Shrish Calla, MD

Family Medicine · Deltona, FLNPI 1497976526

Payments from drug & device makers

$3,257in general payments, 2019–2025

Across 180 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$530
  • AstraZeneca$402
  • AbbVie$335
  • Lilly USA, LLC$263
  • GSK$182
  • Johnson & Johnson$170
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,16697%
  • Education$913%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,257 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$225,191
Medicare patients
356
Services billed
2,667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban191$145,365
OzempicSemaglutide74$93,504
JardianceEmpagliflozin105$78,739
XareltoRivaroxaban71$62,623
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$53,775
MounjaroTirzepatide44$52,137
TrulicityDulaglutide39$38,091
JanuviaSitagliptin Phosphate24$34,603
FarxigaDapagliflozin Propanediol23$25,455
EntrestoSacubitril/Valsartan18$16,907
RybelsusSemaglutide11$12,073
MyrbetriqMirabegron12$11,262
MultaqDronedarone Hcl12$9,585
Atorvastatin Calcium909$8,178
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$8,161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$93$145,365191 claims
Novo NordiskOzempic, Rybelsus$530$105,57785 claims
Lilly USA, LLCMounjaro, Trulicity$263$90,22783 claims
Boehringer IngelheimJardiance, Combivent Respimat$110$84,040116 claims
Johnson & JohnsonXarelto$170$62,62371 claims
GSKTrelegy Ellipta, Breo Ellipta$182$61,03063 claims
MerckJanuvia$115$34,60324 claims
AstraZenecaFarxiga, Symbicort, Crestor$402$33,28851 claims
NovartisEntresto$91$16,90718 claims
Astellas Pharma US IncMyrbetriq$170$11,26212 claims
Sanofi-aventis U.S. LLCMultaq$46$9,58512 claims
Esperion Therapeutics, Inc.Nexlizet$65$7,56212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Deltona

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →